Atossa Therapeutics, Inc. (ATOS) — Financial statements
Income statement, balance sheet, and cash flow for Atossa Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.02↓26.1% | 0.02↑187.5% | 0.01↓65.2% | 0.02 | |
| Gross Profit | 0.00↑100.0% | -0.02↑26.1% | -0.02↓187.5% | -0.01↑65.2% | -0.02 | |
| Operating Expenses | ||||||
| R&D Expenses | 21↑50.1% | 14↓18.6% | 17↑14.9% | 15↑63.8% | 9 | |
| General & Administrative Expenses | 16↑18.2% | 14↓3.8% | 14↑11.4% | 13↑11.5% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 16↑18.2% | 14↓3.8% | 14↑11.4% | 13↑11.5% | 11 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 37↑34.5% | 28↓12.0% | 31↑13.3% | 28↑34.9% | 21 | |
| Total Costs & Expenses | 37↑34.5% | 28↓12.0% | 31↑13.3% | 28↑34.9% | 21 | |
| Operating Results | ||||||
| Operating Income | -37↓34.5% | -28↑12.0% | -31↓13.3% | -28↓34.9% | -21 | |
| Depreciation & Amortization | 0.02↓5.9% | 0.02↓26.1% | 0.02↑187.5% | 0.01↓65.2% | 0.02 | |
| EBITDA | -37↓34.5% | -28↑12.0% | -31↓13.3% | -28↓35.1% | -20 | |
| EBIT | -37↓34.5% | -28↑12.0% | -31↓13.3% | -28↓34.9% | -21 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓41.3% | 4↓6.7% | 4↑395.2% | 0.88↑14516.7% | 0.01 | |
| Interest Income | 2↓41.3% | 4↓6.7% | 4↑395.2% | 0.88↑14516.7% | 0.01 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 2↑12.0% | 2↑65.0% | 1↑75.5% | 0.73↑960.0% | -0.09 | |
| Income Before Tax | -35↓36.3% | -26↑15.3% | -30↓11.6% | -27↓30.8% | -21 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -35↓36.3% | -26↑15.3% | -30↓11.6% | -27↓30.8% | -21 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -35↓36.3% | -26↑15.3% | -30↓11.6% | -27↓30.8% | -21 | |
| Bottom-Line Net Income | -35↓36.3% | -26↑15.3% | -30↓11.6% | -27↓30.8% | -21 | |
| EPS (Basic) | -4.04↓34.7% | -3.00↑16.7% | -3.60↓14.3% | -3.15↓16.7% | -2.70 | |
| EPS (Diluted) | -4.04↓34.7% | -3.00↑16.7% | -3.60↓14.3% | -3.15↓16.7% | -2.70 | |
| Weighted Average Shares | 9↑2.6% | 8↓0.2% | 8↓0.4% | 8↑8.3% | 8 | |
| Weighted Average Diluted Shares | 9↑2.6% | 8↓0.2% | 8↓0.4% | 8↑8.3% | 8 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.